Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408310 | 0.88 | CYP2C9 (0.67) | NPC1RAB9ASMN1; SMN2CYP2C9EPHX1 | |
| SCHEMBL29201540 | 0.86 | CYP2C9 (0.65) | NPC1RAB9ASMN1; SMN2CYP2C9EPHX1 | |
| Fluoride SCHEMBL2310518 | 0.86 | CYP2C9 (0.65) | NPC1RAB9ASMN1; SMN2CYP2C9EPHX1 | |
| Hydrochloric Acid SCHEMBL22076570 | 0.86 | CYP2C9 (0.65) | NPC1RAB9ASMN1; SMN2CYP2C9EPHX1 | |
| Bromide SCHEMBL6851253 | 0.86 | CYP2C9 (0.65) | NPC1RAB9ASMN1; SMN2CYP2C9EPHX1 | |
| SCHEMBL17865779 | 0.85 | LMNA (0.58) | SMN1; SMN2CYP2C9EPHX1MAPTLMNA | |
| SCHEMBL14714456 | 0.85 | NPC1 (0.56) | NPC1RAB9ACTDSP1SMN1; SMN2MAPT | |
| SCHEMBL3037706 | 0.85 | HDAC1 (0.60) | LMNAHTTJAK2 | |
| SCHEMBL13701695 | 0.84 | HDAC8 (0.64) | CTDSP1SMN1; SMN2CYP2C9EPHX1MAPT | |
| SCHEMBL13270520 | 0.83 | JAK2 (0.57) | MAPTLMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105102449-B | Antiviral compound | 豪夫迈·罗氏有限公司 | 2017-06-13 | — | — | CN | disclosed |
| US-20160168185-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | BAYLOR COLLEGE OF MEDICINE (US) | 2016-06-16 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
| US-6080870-A | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors | MERCK & CO., INC. (US) | 2000-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | NPC1 2180/4885RAB9A 2498/4885CTDSP1 1114/4885 |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | NPC1 1477/4885RAB9A 2708/4885CTDSP1 2363/4885 |
| US-20160168185-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | DOT1L, CARM1, NSD1 | NPC1 1162/4885RAB9A 1932/4885CTDSP1 505/4885 |
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | NPC1 300/4885RAB9A 788/4885CTDSP1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.